Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

290 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2022-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study a mistletoe preparation (Iscador Qu) is added to standard therapy in inoperable pancreatic cancer in order to evaluate effect on overall survival and health-related quality of life. Half of participants will take subcutaneous injections with mistletoe in addition to standard therapy (palliative chemotherapy or best supportive care); the other half will receive a placebo and standard therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)

NCT01448668

Pancreas Cancer

UNKNOWN

Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer

NCT03984214

Pancreatic Cancer Non-resectable Chemotherapy-induced Nausea and Vomiting Pancreatic Cancer Metastatic

COMPLETED PHASE3

Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors

NCT06408688

Advanced Solid Tumor

RECRUITING PHASE4

Iscar for Supplemental Care in Stage IV Lung Cancer

NCT00079794

Lung Cancer

COMPLETED PHASE2

Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)

NCT01448655

Colorectal Cancer

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Extracts from European mistletoe (Viscum album L.) have been used as complementary cancer therapy since the 1920s. To date over 160 clinical studies on mistletoe in cancer therapy have been conducted with varying quality; the therapy is still controversial.

Best evidence is found for increase of health-related quality of life (HRQoL) and reduction of side effects of conventional therapies (chemotherapy, radiation) in breast cancer patients. Mistletoe treatment is described as safe and well tolerated. There are some clinical studies supporting the use of mistletoe extract in the management of late stage cancer.

Statistically significant effects on overall survival (OS) and HRQoL in pancreatic cancer patients have recently been shown in a randomized open label trial in Serbia investigating the addition of mistletoe extract to best supportive care. The results are questioned because patients knew what kind of treatment they received.

Mistletoe extracts are usually administered subcutaneously. They contain a multitude of substances with immune modulatory and cytotoxic or - in animal studies - antitumorigenic, anti-metastatic and antiangiogenic effects.

This trial investigates whether there is a beneficial effect of mistletoe extracts on OS and HRQoL in pancreatic cancer patients receiving standard treatment (palliative chemotherapy or best supportive care).

Inclusion has started at 4 study centers (2 more centers are waiting for participation). And participants are randomized 1:1 to mistletoe treatment (Iscador Qu®) given in increasing dosage from 0,01mg to 20 mg or placebo injections subcutaneously 3 times /week. Stratification will be performed for received oncological treatment (palliative chemotherapy or best supportive care). At 7 visits in 9 months, participants fill in the validated EORTC QLQ-C30 (QLO=quality of life questionnaire) and PAN-26 (PAN=pancreas) quality of life questionnaires. Body weight, use of cancer-related medicines, substitution of nutrition, adverse events need of supportive care and inpatient care are measured. To be able to assess more dimensions of quality of life than possible with questionnaires, a qualitative sub-study with interviews on about 30 participants in this trial is performed in month 3. A 2nd substudy has been added november 2016 to elucidate the systemic effects of mistletoe therapy and to explore potential prognostic and predictive biomarkers (anticipated n=100).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mistletoe extract (Iscador Qu)

Fermented aqueous extract of Viscum album ssp album (L.) (mistletoe) = Iscador Qu, subcutaneous use 3 injections/week; dose escalation from 0,01mg - 20mg

Group Type EXPERIMENTAL

Mistletoe extract (Iscador Qu)

Intervention Type DRUG

1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg

Placebo

isotonic saline solution, subcutaneous use 3 injections/week

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

1ml subcutaneous injection 3 times/week

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mistletoe extract (Iscador Qu)

1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg

Intervention Type DRUG

Placebo

1ml subcutaneous injection 3 times/week

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fermented aqueous extract of Viscum album ssp album (L.) Isotonic saline solution

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Signed written informed consent

* Age ≥ 18 years
* Inoperable locally advanced or metastatic pancreatic cancer or relapse of pancreatic cancer.

* Primary diagnosis: if histology is not clinically achievable diagnosis is to be confirmed according to local practice sufficient for diagnosis and choice of therapy (such as CA19-9 (=cancer antigen 19-9) and CT).
* Relapse: histology (not required) or diagnosis according to local practice such as clinical signs and/or imaging and/or CA19-9.
* ECOG ( Eastern Cooperative Oncology Group) performance status 0-2 (see table in section 12.14 )
* Adequate negative pregnancy test and adequate contraception (where appropriate)

Exclusion Criteria

Life expectancy less than 4 weeks

* Pregnancy or breastfeeding
* Neuroendocrine tumors of the pancreas (NET)
* Current use of interferon, G-CSF (granulocyte colony-stimulating factor) and thymus preparations
* Symptomatic brain edema due to brain metastases
* Known hypersensitivity to mistletoe-containing products
* Current use of mistletoe extract preparations in any form
* Chronic granulomatous disease or active autoimmune disease or autoimmune disease with immunosuppressive treatment
* Medical, psychiatric, cognitive or other conditions that may compromise the patient´s ability to understand the patient information, give informed consent, comply with the study protocol or complete the study (e.g. needle phobia).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No